Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 98793 | 3.305 |
09:34 ET | 54486 | 3.295 |
09:36 ET | 14027 | 3.3 |
09:38 ET | 39193 | 3.3399 |
09:39 ET | 45359 | 3.325 |
09:41 ET | 8750 | 3.315 |
09:43 ET | 7004 | 3.3009 |
09:45 ET | 20682 | 3.29 |
09:48 ET | 10570 | 3.285 |
09:50 ET | 21808 | 3.295 |
09:52 ET | 31397 | 3.315 |
09:54 ET | 13849 | 3.315 |
09:56 ET | 36229 | 3.315 |
09:57 ET | 30678 | 3.295 |
09:59 ET | 49436 | 3.291 |
10:01 ET | 80733 | 3.285 |
10:03 ET | 26102 | 3.275 |
10:06 ET | 86586 | 3.265 |
10:08 ET | 86451 | 3.255 |
10:10 ET | 124092 | 3.255 |
10:12 ET | 20095 | 3.265 |
10:14 ET | 47296 | 3.255 |
10:15 ET | 52319 | 3.265 |
10:17 ET | 16450 | 3.26 |
10:19 ET | 16210 | 3.255 |
10:21 ET | 39931 | 3.25 |
10:24 ET | 24414 | 3.24 |
10:26 ET | 35625 | 3.25 |
10:28 ET | 16133 | 3.255 |
10:30 ET | 27051 | 3.245 |
10:32 ET | 40306 | 3.245 |
10:33 ET | 22496 | 3.235 |
10:35 ET | 89696 | 3.265 |
10:37 ET | 69010 | 3.2697 |
10:39 ET | 18703 | 3.26 |
10:42 ET | 5828 | 3.265 |
10:44 ET | 43461 | 3.26 |
10:46 ET | 14906 | 3.24 |
10:48 ET | 45144 | 3.255 |
10:50 ET | 31642 | 3.25 |
10:51 ET | 45965 | 3.255 |
10:53 ET | 8700 | 3.255 |
10:55 ET | 162788 | 3.235 |
10:57 ET | 85036 | 3.245 |
11:00 ET | 44688 | 3.245 |
11:02 ET | 27239 | 3.245 |
11:04 ET | 5601 | 3.245 |
11:06 ET | 119833 | 3.24 |
11:08 ET | 5240 | 3.2401 |
11:09 ET | 20260 | 3.235 |
11:11 ET | 10333 | 3.235 |
11:13 ET | 19770 | 3.235 |
11:15 ET | 17959 | 3.24 |
11:18 ET | 39444 | 3.245 |
11:20 ET | 52859 | 3.255 |
11:22 ET | 4049 | 3.255 |
11:24 ET | 124996 | 3.24 |
11:26 ET | 53001 | 3.235 |
11:27 ET | 113092 | 3.235 |
11:29 ET | 144706 | 3.25 |
11:31 ET | 25088 | 3.255 |
11:33 ET | 3906 | 3.255 |
11:36 ET | 124370 | 3.285 |
11:38 ET | 159290 | 3.305 |
11:40 ET | 25651 | 3.31 |
11:42 ET | 3912 | 3.305 |
11:44 ET | 26476 | 3.295 |
11:45 ET | 98164 | 3.28 |
11:47 ET | 18947 | 3.275 |
11:49 ET | 42582 | 3.265 |
11:51 ET | 77824 | 3.26 |
11:54 ET | 9089 | 3.26 |
11:56 ET | 72959 | 3.265 |
11:58 ET | 7107 | 3.265 |
12:00 ET | 77730 | 3.265 |
12:02 ET | 34299 | 3.265 |
12:03 ET | 17225 | 3.26 |
12:05 ET | 2562 | 3.25 |
12:07 ET | 836 | 3.255 |
12:09 ET | 10600 | 3.255 |
12:12 ET | 12473 | 3.255 |
12:14 ET | 6544 | 3.25 |
12:16 ET | 5173 | 3.255 |
12:18 ET | 6080 | 3.255 |
12:20 ET | 1900 | 3.255 |
12:21 ET | 307134 | 3.255 |
12:23 ET | 34168 | 3.245 |
12:25 ET | 3766 | 3.245 |
12:27 ET | 28617 | 3.24 |
12:30 ET | 41250 | 3.255 |
12:32 ET | 4372 | 3.25 |
12:34 ET | 5823 | 3.255 |
12:36 ET | 1150 | 3.25 |
12:38 ET | 39519 | 3.255 |
12:39 ET | 3000 | 3.255 |
12:41 ET | 3417 | 3.255 |
12:43 ET | 5129 | 3.255 |
12:45 ET | 112707 | 3.27 |
12:48 ET | 1800 | 3.275 |
12:50 ET | 22382 | 3.29 |
12:52 ET | 7010 | 3.285 |
12:54 ET | 7250 | 3.28 |
12:56 ET | 11281 | 3.285 |
12:57 ET | 2200 | 3.285 |
12:59 ET | 22799 | 3.29 |
01:01 ET | 8410 | 3.29 |
01:03 ET | 8664 | 3.28 |
01:06 ET | 5400 | 3.285 |
01:08 ET | 87938 | 3.2825 |
01:10 ET | 29543 | 3.28 |
01:12 ET | 31118 | 3.285 |
01:14 ET | 4189 | 3.29 |
01:15 ET | 2450 | 3.285 |
01:17 ET | 5700 | 3.285 |
01:19 ET | 4893 | 3.28 |
01:21 ET | 24887 | 3.3 |
01:24 ET | 4700 | 3.295 |
01:26 ET | 42441 | 3.28 |
01:28 ET | 22671 | 3.295 |
01:30 ET | 1400 | 3.295 |
01:32 ET | 12764 | 3.295 |
01:33 ET | 18385 | 3.29 |
01:35 ET | 33853 | 3.285 |
01:37 ET | 4040 | 3.2863 |
01:39 ET | 6742 | 3.285 |
01:42 ET | 2812 | 3.28 |
01:44 ET | 10436 | 3.285 |
01:46 ET | 7478 | 3.28 |
01:48 ET | 6646 | 3.285 |
01:50 ET | 11182 | 3.28 |
01:51 ET | 9968 | 3.285 |
01:53 ET | 5727 | 3.28 |
01:55 ET | 14699 | 3.285 |
01:57 ET | 29705 | 3.29 |
02:00 ET | 10568 | 3.295 |
02:02 ET | 13549 | 3.285 |
02:04 ET | 12262 | 3.285 |
02:06 ET | 36589 | 3.295 |
02:08 ET | 6644 | 3.3 |
02:09 ET | 14417 | 3.3 |
02:11 ET | 20189 | 3.305 |
02:13 ET | 32546 | 3.31 |
02:15 ET | 6899 | 3.31 |
02:18 ET | 35333 | 3.305 |
02:20 ET | 25515 | 3.3126 |
02:22 ET | 8663 | 3.31 |
02:24 ET | 15644 | 3.305 |
02:26 ET | 12766 | 3.31 |
02:27 ET | 2311 | 3.3 |
02:29 ET | 18979 | 3.31 |
02:31 ET | 19913 | 3.3 |
02:33 ET | 43800 | 3.295 |
02:36 ET | 34162 | 3.305 |
02:38 ET | 15388 | 3.305 |
02:40 ET | 25757 | 3.32 |
02:42 ET | 3399 | 3.315 |
02:44 ET | 13843 | 3.325 |
02:45 ET | 18072 | 3.3212 |
02:47 ET | 26812 | 3.315 |
02:49 ET | 3520 | 3.31 |
02:51 ET | 3602 | 3.31 |
02:54 ET | 3148 | 3.315 |
02:56 ET | 19128 | 3.325 |
02:58 ET | 11880 | 3.32 |
03:00 ET | 16744 | 3.325 |
03:02 ET | 12291 | 3.325 |
03:03 ET | 14500 | 3.33 |
03:05 ET | 7532 | 3.33 |
03:07 ET | 64650 | 3.345 |
03:09 ET | 50998 | 3.34 |
03:12 ET | 27503 | 3.335 |
03:14 ET | 5800 | 3.33 |
03:16 ET | 16053 | 3.33 |
03:18 ET | 10876 | 3.34 |
03:20 ET | 16087 | 3.34 |
03:21 ET | 6369 | 3.335 |
03:23 ET | 58244 | 3.35 |
03:25 ET | 12985 | 3.34 |
03:27 ET | 13949 | 3.35 |
03:30 ET | 20688 | 3.34 |
03:32 ET | 38163 | 3.345 |
03:34 ET | 12920 | 3.34 |
03:36 ET | 14415 | 3.345 |
03:38 ET | 51828 | 3.36 |
03:39 ET | 4602 | 3.36 |
03:41 ET | 19520 | 3.355 |
03:43 ET | 8467 | 3.355 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.0B | -9.7x | --- |
Vera Therapeutics Inc | 2.0B | -18.1x | --- |
Rocket Pharmaceuticals Inc | 1.9B | -7.3x | --- |
Fusion Pharmaceuticals Inc | 1.8B | -15.1x | --- |
CG Oncology Inc | 2.2B | -28.6x | --- |
Inhibrx Inc | 1.8B | -6.4x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.0B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.41 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -9.7x |
Price/Sales (TTM) | 3,821.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.